Login to Your Account



Angiogenesis: Paradigm Changes For Judging 'Success' Of Drugs

By Randall Osborne


Monday, May 13, 2002
The failure early this month of Ribozyme Pharmaceuticals Inc.'s Angiozyme in a Phase II trial as a monotherapy against Stage IV metastatic breast cancer was enough to feed another round in the sporadic, ongoing debate over angiogenesis inhibitors. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription